Cencora distribution deal boosts Citius shares

[Gratitude Concept With Heart Symbol]
Eoneren

* Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]), reached a distribution services agreement with the medical distributor Cencora (NYSE:COR [https://seekingalpha.com/symbol/COR]) for its lymphoma therapy, Lymphir.
* Under the agreement, Cencora (NYSE:COR [https://seekingalpha.com/symbol/COR]) is expected to become a wholesale distributor for Lymphir, an immunotherapy approved by the FDA in August 2024 for adults with relapsed or refractory cutaneous T-cell lymphoma.
* The deal, which builds on an existing distribution services agreement between the two companies, is set to widen Citius Oncology's (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]) commercial distribution network, boosting the drug’s availability upon its market entry in the U.S.
* "As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities,” CEO of Citius Pharma (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]) and Citius Oncology (NASDAQ:CTOR [https://seekingalpha.com/symbol/CTOR]) Leonard Mazur remarked. [https://seekingalpha.com/pr/20165973-citius-oncology-expands-distribution-network-for-lymphir-with-execution-of-distribution]

MORE ON CITIUS PHARMACEUTICALS, CENCORA, ETC.

* Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs [https://seekingalpha.com/article/4787549-cencora-continues-to-deliver-as-a-healthcare-distributor-with-further-growth-signs]
* Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4782949-cencora-inc-cor-q2-2025-earnings-call-transcript]
* Cencora, Inc. 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4782871-cencora-inc-2025-q2-results-earnings-call-presentation]
* Citius Pharmaceuticals slides on $15.8M securities offering [https://seekingalpha.com/news/4456818-citius-pharmaceuticals-announces-registered-direct-offering-of-158-million]
* Citius Oncology enters distribution services agreement with Cardinal Health [https://seekingalpha.com/news/4456523-citius-oncology-enters-distribution-services-agreement-with-cardinal-health]